DPP-4 inhibitor treatment: β-cell response but not HbA_1c reduction is dependent on the duration of diabetes

Figures & data

Table 1 Demographic and clinical characteristics of the participants by study and treatment group

Characteristics	Monotherapy A2301^Citation6		Monotherapy A2384^Citation7		Add-on to metformin A2303^Citation8		Add-on to TZD A2304^Citation9		Add-on to SU A2305^Citation10		Add-on to insulin A23135^Citation11
	Vilda (n=152)	Pbo (n=160)	Vilda (n=83)	Pbo (n=92)	Vilda (n=185)	Pbo (n=182)	Vilda (n=158)	Pbo (n=158)	Vilda (n=132)	Pbo (n=144)	Vilda (n=228)	Pbo (n=221)
n (ISR/G)	8	10	19	19	58	54	49	43	21	23	167	144
Age, years	52.8±9.6	52.2±11.2	50.2±12.7	52.0±12.0	53.9±9.5	54.5±10.3	54.0±9.2	54.8±10.6	58.2±11.1	57.9±10.5	59.3±9.9	59.1±10.1
Duration of T2DM, years	2.1±3.3	1.6±2.5	2.4±3.2	2.5±3.7	5.8±4.7	6.2±5.3	4.6±4.8	4.8±4.6	6.7±5.3	7.8±5.8	12.9±6.9	13.2±7.9
Baseline HbA1c, %	8.6±0.8	8.4±0.8	8.4±0.9	8.5±0.8	8.4±1.0	8.3±0.9	8.7±1.2	8.7±1.2	8.6±1.0	8.5±1.0	8.8±1.0	8.8±1.0
End of study HbA1c, %	7.6±1.5	8.1±1.5	7.7±1.4	8.4±1.5	7.5±1.2	8.5±1.5	7.7±1.5	8.4±1.7	7.9±1.3	8.6±1.4	7.7±1.1	8.4±1.2
Baseline ISR/Ga	15.3±6.1	16.5±4.2	23.6±12.0	31.5±21.8	20.0±7.3	20.3±8.3	18.9±8.4	20.8±9.5	19.3±7.4	19.7±6.4	8.3±5.0	8.0±4.1
End of Study ISR/Ga	31.6±17.4	20.4±11.6	30.3±12.1	31.3±23.0	26.6±9.4	21.4±10.1	25.9±10.9	22.6±10.0	22.7±7.8	18.1±5.9	11.5±8.2	8.6±4.7

Notes:

a pmol/min/m²/mmol/L. All values are mean ± SD unless specified. ‘n’ values denote the number of patients randomized to the respective treatment group.

Abbreviations: HbA_1c, glycated hemoglobin; ISR/G, insulin secretory rate relative to glucose; Pbo, placebo; SU, sulfonylurea; TZD, thiazolidinedione; T2DM, type 2 diabetes mellitus; Vilda, vildagliptin.

Figure 1 Association between mean difference (vilda–pbo) in ISR/G change from baseline and mean difference (vilda–pbo) in HbA_1c change from baseline vs mean duration of diabetes at baseline.

Abbreviations: HbA_1c, glycated hemoglobin; ISR/G, insulin secretory rate relative to glucose; pbo, placebo; vilda, vildagliptin.

DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res200739321822317373638

 PubMed Web of Science ®Google Scholar

Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract200776113213817223217

 PubMed Web of Science ®Google Scholar

BosiECamisascaRPColloberCRochotteEGarberAJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care200730489089517277036

 PubMed Web of Science ®Google Scholar

GarberAJSchweizerABaronMARochotteEDejagerSVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab20079216617417300592

 PubMed Web of Science ®Google Scholar

GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylureaDiabetes Obes Metab200810111047105618284434

 PubMed Web of Science ®Google Scholar

KothnyWFoleyJKozlovskiPShaoQGallwitzBLukashevichVImproved glycemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitusDiabetes Obes Metab201315325225723039321

 PubMed Web of Science ®Google Scholar